Jeffrey Statland

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Primary lateral sclerosis: consensus diagnostic criteria

Martin R. Turner, Richard J. Barohn, Philippe Corcia et al. · Journal of Neurology Neurosurgery & Psychiatry · 2020 · 228 citations · Full text

Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis, Motor Dysfunction +12

Somatodendritic Kv7/KCNQ/M Channels Control Interspike Interval in Hippocampal Interneurons

J. Josh Lawrence, Fernanda Saraga, Joseph F. Churchill et al. · Journal of Neuroscience · 2006 · 189 citations · Full text

Mexiletine for Symptoms and Signs of Myotonia in Nondystrophic Myotonia

Jeffrey Statland · JAMA · 2012 · 181 citations · Full text

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3